• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pharma delivers another beat & raise quarter for Johnson & Johnson

Pharma delivers another beat & raise quarter for Johnson & Johnson

July 15, 2014 By Brad Perriello

Pharma delivers another beat & raise quarter for Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) managed to top expectations with its 2nd-quarter results today, largely on the strength of its pharmaceuticals business, but its medical device division once again failed to meet the forecast.

New Brunswick, N.J.-based Johnson & Johnson posted profits of $4.33 billion, or $1.51 per share, on sales of $19.50 billion for the 3 months ended June 30, for bottom-line growth of 12.9% on sales growth of 9.1%.

Adjusted to exclude 1-time items, earnings per share reached $1.66, a full 11¢ above expectations on Wall Street. The strong results prompted J&J to boost its earnings guidance for 2014 to $5.85 to $5.92 per share, up from $5.80 to $5.90.

"Our strong 2nd-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," chairman & CEO Alex Gorsky said in prepared remarks. "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."

The pharmaceuticals business delivered 21.1% overall growth, rising to $8.52 billion, with U.S. pharma sales surging 36.6% to $4.61 billion. But Johnson & Johnson’s medical device & diagnostics business saw meager revenue growth of 0.7%, to $7.24 billion overall, with U.S. MD&D sales falling -1.4% to $3.20 billion.

"Primary contributors to operational growth were hip and trauma products in the orthopaedics business, Biosense Webster’s electrophysiology products in the cardiovascular care business, and sales of energy products in the specialty surgery business," the company said.

J&J’s cardiovascular business delivered sales growth of 7.2%, rising to $567 million for the quarter. The orthopedics unit reported sales of $2.47 billion, up 3.5% worldwide; the specialty surgery business logged overall sales of $905 million, up 1.7%. Johnson & Johnson’s surgical care division saw revenues of $1.58 billion, off -0.8%.

In the U.S., cardiovascular sales rose 4.9% to $214 million. Orthopedics sales in the U.S. were 1.29 billion, up 1.6%, while specialty surgery revenues slid -0.5% to $424 million during the 2nd quarter. U.S. surgical care sales dropped -4.5% to $551 million, Johnson & Johnson said.

JNJ shares were down 1.9% to $103.40 apiece as of about 10 a.m. today.

Filed Under: MassDevice Earnings Roundup, News Well, Pharmaceutical, Wall Street Beat Tagged With: Johnson and Johnson, Q2

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy